Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A | Q14432 | 3/20 | 0.31 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | ALB | P02768 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.31 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.31 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.31 |
| ▸ | POLG | P54098 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30867003 | 0.79 | FGFR1 (0.31) | — | |
| SCHEMBL13470539 | 0.78 | CRBN (0.31) | — | |
| SCHEMBL21099848 | 0.77 | PDE3A (0.32) | PDE3ACACNA1FLMNAALBMAPT | |
| SCHEMBL13454602 | 0.72 | NT5E (0.35) | PDE3ALMNAPDE4DSLC29A1 | |
| SCHEMBL13454604 | 0.72 | NT5E (0.35) | PDE3ALMNAPDE4DSLC29A1 | |
| SCHEMBL21099941 | 0.72 | PDE3A (0.34) | PDE3ACACNA1FLMNAALBMAPT | |
| SCHEMBL21100416 | 0.71 | PDE3A (0.45) | PDE3ACACNA1FLMNAALBMAPT | |
| SCHEMBL21099800 | 0.71 | PDE3A (0.36) | PDE3ACACNA1FLMNAALBMAPT | |
| SCHEMBL21099906 | 0.67 | NT5E (0.38) | PDE3ACACNA1FLMNAALBMAPT | |
| SCHEMBL13454896 | 0.66 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120263678-A1 | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120263678-A1 | 1'-SUBSTITUTED PYRIMIDINE N-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NUDT1, TYMP | PDE3A 1827/4885CACNA1F 3935/4885LMNA 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.